期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
1
作者 Bin Tu Huiyuan Wang +6 位作者 Xinran An jingkun qu Qianqian Li Yanrong Gao Mingjie Shi Hong Qiu Yongzhuo Huang 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2022年第7期3187-3194,共8页
To the Editor:As of January 27,2022,there were 363,062,293 cases and 5,645,884deaths from the COVID-19 pandemic1.The prevalent mutated strains have aggravated the global pandemic2.SARS-Co V-2 is highly mutable,and the... To the Editor:As of January 27,2022,there were 363,062,293 cases and 5,645,884deaths from the COVID-19 pandemic1.The prevalent mutated strains have aggravated the global pandemic2.SARS-Co V-2 is highly mutable,and the mutations on the spike(S)protein resulted in a high transmission of COVID-19 and vaccine breakthrough infection3.For example,there is a notable decrease in neutralizing ability of BNT162b2 vaccination-elicited antibodies against the Delta and other variants4,5,and attenuation of peak viral burden and vaccine effectiveness are reduced with Delta variant6. 展开更多
关键词 SARS-CoV-2 Delta variant Heparan sulfate Spike protein Heparin nanoparticle Pulmonary delivery
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部